372 related articles for article (PubMed ID: 30018749)
1. Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.
Cullell N; Carrera C; Muiño E; Torres N; Krupinski J; Fernandez-Cadenas I
Oncotarget; 2018 Jun; 9(49):29238-29258. PubMed ID: 30018749
[TBL] [Abstract][Full Text] [Related]
2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database.
Barbieri MA; Cutroneo PM; Baratelli C; Cicala G; Battaglia A; Santoro V; Andò G; Spina E
J Clin Pharm Ther; 2021 Aug; 46(4):1027-1040. PubMed ID: 33646603
[TBL] [Abstract][Full Text] [Related]
4. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Alcocer L
Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenomic Research in Direct Oral Anticoagulants].
Liu XM; DU LP; Liu B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Aug; 42(4):562-565. PubMed ID: 32895112
[TBL] [Abstract][Full Text] [Related]
7. Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation.
Stacy Z; Richter S
Clin Appl Thromb Hemost; 2017 Jan; 23(1):5-19. PubMed ID: 26988835
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka MS; Lip GY
Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
[TBL] [Abstract][Full Text] [Related]
9. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants.
Kanuri SH; Kreutz RP
J Pers Med; 2019 Jan; 9(1):. PubMed ID: 30658513
[TBL] [Abstract][Full Text] [Related]
11. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
12. Oral Anticoagulants after Heart Transplantation-Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants.
Darche FF; Fabricius LC; Helmschrott M; Rahm AK; Ehlermann P; Bruckner T; Sommer W; Warnecke G; Frey N; Rivinius R
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445369
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
14. Association of Direct Oral Anticoagulants vs. Vitamin K Antagonists With Fractures in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis.
Wu X; Hu L; Liu J; Gu Q
Front Cardiovasc Med; 2021; 8():713187. PubMed ID: 34368263
[No Abstract] [Full Text] [Related]
15. Old and new oral anticoagulants: Food, herbal medicines and drug interactions.
Di Minno A; Frigerio B; Spadarella G; Ravani A; Sansaro D; Amato M; Kitzmiller JP; Pepi M; Tremoli E; Baldassarre D
Blood Rev; 2017 Jul; 31(4):193-203. PubMed ID: 28196633
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants.
Weitz JI; Jaffer IH; Fredenburgh JC
F1000Res; 2017; 6():985. PubMed ID: 28713563
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
18. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
Darius H
Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
[TBL] [Abstract][Full Text] [Related]
19. Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.
Schuh T; Reichardt B; Finsterer J; Stöllberger C
J Thromb Thrombolysis; 2016 Oct; 42(3):447-51. PubMed ID: 27221106
[TBL] [Abstract][Full Text] [Related]
20. Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants.
Frenkel Rutenberg T; Velkes S; Vitenberg M; Leader A; Halavy Y; Raanani P; Yassin M; Spectre G
Thromb Res; 2018 Jun; 166():106-112. PubMed ID: 29727737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
